Bechara FG, Podda M, Prens EP, et al. - Adalimumab was found to be effective in conjunction with wide-excision surgery followed by secondary intention healing, with no need to interrupt treatment prior to surgery. There is a need for further evaluation of adalimumab as an adjuvant therapy to surgery in patients with moderate to severe hidradenitis suppurativa (HS).

• Researchers recruited a total of 103 patients. Individuals were assigned randomly to adalimumab and 103 to matching placebo.

• In this study, 51% (n = 106) were women, 94% (n = 193) were White among all patients, and the mean (SD) age was 37.6 (11.3) years.

• According to the results, significantly more patients receiving adalimumab (49 of 103 [48%]) vs placebo (35 of 103 [34%]; P = .049) achieved HS clinical response across all body regions (treatment difference, 14% [95% CI, 0%-27%]) at week 12.

• They observed treatment-emergent adverse events in 74 of 103 patients (72%) and 69 of 103 patients (67%) in the adalimumab and placebo groups, respectively.

• There was no elevated risk of postoperative wound infection, complication, or hemorrhage with adalimumab vs placebo.

• There were two deaths in the adalimumab group; neither was considered as having a reasonable possibility of a relationship to study drug.